Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Evaluation of Xerostomia Following 3 Dimensional Conformal Radiotherapy for Nasopharyngeal Cancer Patients

3차원 입체조형 방사선치료를 시행받은 코인두암 환자에서의 구강건조증 분석

  • Park Young-Je (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park Won (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ju Sang-Gyu (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Nam Hee-Rim (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Oh Dong-Ryul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Park Hee-Chul (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ahn Yong-Chan (Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 박영제 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박원 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 주상규 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 남희림 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 오동렬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 박희철 (성균관대학교 의과대학 삼성서울병원 방사선종양학과) ;
  • 안용찬 (성균관대학교 의과대학 삼성서울병원 방사선종양학과)
  • Published : 2006.06.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purose: This study is to evaluate the xerostomia following 3-dimensional conformal radiation therapy (3D CRT) in nasopharynx cancer patients using the xerostomia questionnaire score (XQS). Materials and Methods: Questionnaire study was done on 51 patients with nasopharynx cancer who received 3D CRT from Dec. 2000 to Aug. 2005. 3D CRT technique is based on 'serial shrinking field' concept by 3 times of computed tomography (CT) simulation. Total target dose to the primary tumor was 72 Gy with 1.8 Gy daily fractions. Xerostomia was assessed with 4-questions XQS, and the associations between XQS and time elapsed after RT, age, sex, stage, concurrent chemotherapy, and parotid dose were analyzed. Results: Concurrent chemotherapy was given to 40 patients and RT alone was given to 11 patients. The median time elapsed after 3D CRT was 20 ($1{\sim}58$) months and the mean XQS of all 51 patients was $8.4{\pm}1.9\;(6{\sim}14)$. XQS continuously and significantly decreased over time after 3D CRT ($X^2$=-0.484, p<0.05). There was no significant difference in XQS according to sex, age, and stag. However, XQS of concurrent chemotherapy patients was significantly higher than RT alone patients (P=0.001). XQS of patients receiving total mean parotid dose ${\ge}35 Gy$ was significantly higher than <35 Gy (p=0.05). Decreasing tendency of XQS over time after 3D CRT was observed. Concurrent chemotherapy and total mean parotid dose ${\ge}35 Gy$ were suggested to adversely affect radiation-induced xerostomia.

목적: 3차원 입체조형 방사선치료를 시행 받은 코인두암 환자에서 설문조사를 이용하여 구강건조증의 시간경과에 따른 변화양상을 분석하고자 하였다. 대상 및 방법: 2000년 12월부터 2005년 8월까지 코인두암 환자에서 3차원 입체조형 방사선치료를 적용한 환자 51명을 설문조사의 대상으로 하였다. 3차원 입체조형 방사선치료는 3회의 컴퓨터 단층촬영(Computed tomography: CT)모의치료를 이용한 3단계 치료계획을 시행하는 순차적 조사영역 축소방법을 사용하였고, 총 선량 72 Gy를 목표로 하였다. 구강건조증은 일상생활에서 중요한 4가지 항목으로 구성된 설문점수(xerostomia questionnaire score: XQS)를 측정하였으며, 방사선치료 후 경과시간, 성별, 나이, 병기, 항암치료의 병용유무, 그리고 이하선의 평균 방사선량 등에 따르는 차이를 분석하였다. 결과: 항암치료를 병용한 환자가 40명, 방사선치료 단독환자가 11명이었으며, 방사선치료 후 설문조사까지 경과 시간은 중앙값 20 ($1{\sim}58$)개월이었다. 전체 환자에서 XQS 점수의 평균은 8.4점(최하 6점, 최고 14점, 표준편차 1.9)이었다. 방사선치료 후 경과시간에 따라 XQS 점수는 통계적으로 유의하게 감소하는 경향을 보였다($X^2$=-0.484, p<0.05). 성별, 나이, 병기에 따라 XQS 점수의 차이는 없었고, 항암치료를 병용한 환자에서 방사선치료 단돈 환자와 비교하여 XQS 점수가 유의하게 높았다(p=0.001). 전체 이하선의 평균선량은 35 Gy 미만에서 35 Gy 이상보다 XQS 점수가 통계적으로 유의하게 낮았다(p=0.05). 결론: 코인두암 환자에서 3차원 입체조형 방사선치료 후 측정한 XQS 점수는 방사선치료 후 시간경과에 따라 감소하는 양상을 보였으며, 항암치료를 병용함으로써 더 악화되는 경향이 있고, 이하선에 조사되는 평균선량을 35Gy 미만으로 하는 것이 구강건조증 증상완화에 도움이 될 수 있겠다.

Keywords

References

  1. Vissink A, Panders AK, Gravenmade EJ, et al. The causes and consequences of hyposalivation. Ear Nose Throat 1988;67:166-176
  2. Yeh CK, Johnson DA, Dodds MW. Impact of aging on human salivary gland function: a community based study. Aging 1998; 10:421-428
  3. Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid-sparing irradiation of head-andneck cancer. Int J Radiat Oncol Biol Phys 2001;50:695-703 https://doi.org/10.1016/S0360-3016(01)01512-7
  4. Jen YM, Shin R, Lin YS, et al. Parotid gland-sparing 3- dimensional conformal radiotherapy results in less severe dry mouth in nasopharyngeal cancer patients: a dosimetric and clinical comparison with conventional radiotherapy. Radiother Oncol 2005;75:204-209 https://doi.org/10.1016/j.radonc.2005.03.005
  5. Braam PM, Roesink JM, Moerland MA, et al. Long-term parotid gland function after radiotherapy. Int J Radiat Oncol Biol Phys 2005;50:695-703
  6. Lim JH, Kim GW, Keum KC, et al. Parotid sparing radiotherapy technique using 3-D conformal radiotherapy for nasopharyngeal carcinoma. J Korean Soc Ther Radiol Oncol 2000; 18:1-10
  7. Malouf JG, Aragon C, Henson BS, et al. Influence of parotid-sparing radiotherapy on xerostomia in head and neck cancer patients. Cancer Detection and Prevention 2003;27: 305-310 https://doi.org/10.1016/S0361-090X(03)00095-3
  8. Chao KSC, Deasy JO, Markman J, et al. A prospective study of salivary function sparing in patients with head and neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys 2001;51:938-946 https://doi.org/10.1016/S0360-3016(01)01717-5
  9. Ng MK, Porceddu SV, Milner AD, et al. Parotid-sparing Radiotherapy: does it really reduce xerostomia? Clin Oncol 2005;17:610-617 https://doi.org/10.1016/j.clon.2005.06.012
  10. Lee SH, Kim TH, Chie EK, et al. Evaluation of xerostomia following intensity modulated radiotherapy (IMRT) for head and neck cancer patients. J Korean Soc Ther Radiol Oncol 2004; 22:106-114
  11. Kwong DL, Pow EH, Sham JS, et al. Intensity-modulated radiotherapy for early-stage nasopharyngeal carcinoma. Cancer 2004;101:1584-1593 https://doi.org/10.1002/cncr.20552
  12. Amosson CM, Teh BS, Van TJ, et al. Dosimetric predictors of xerostomia for head and neck cancer patients treated with the smart (simultaneous modulated accelerated radiation therapy) boost technique. Int J Radiat Oncol Biol Phys 2003;56:136- 144 https://doi.org/10.1016/S0360-3016(03)00093-2
  13. Wu Q, Manning M, Schmidt-Ullirich R, et al. The potential for sparing of parotids and escalation of biologically equivalent dose with intensity modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 2000;46:195-205 https://doi.org/10.1016/S0360-3016(99)00304-1
  14. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 1998;16:1310-1317 https://doi.org/10.1200/JCO.1998.16.4.1310
  15. Chan AT, Teo PM, Ngan RK, et al. Concurrent chemotherapy- radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progressionfree survival analysis of a phase III randomized trial. J Clin Oncol 2002;20:2038-2044 https://doi.org/10.1200/JCO.2002.08.149
  16. Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol 2003;21:631-637 https://doi.org/10.1200/JCO.2003.06.158
  17. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol 2004;22:2643-2653 https://doi.org/10.1200/JCO.2004.05.173
  18. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with AJCC/UICC (1997) stage 3 and 4 nasopharyngeal cancer of the endemic variety. J Clin Oncol 2005;23:6730-6738 https://doi.org/10.1200/JCO.2005.16.790
  19. Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;62:672-679 https://doi.org/10.1016/j.ijrobp.2004.11.002
  20. Bjordal K, Kaasa S, Mastekaasa A. Quality of life in patients treated for head and neck cancer: a follow up study 7 to 11 years after radiotherapy. Int J Radiat Oncol Biol Phys 1994;28:847-856 https://doi.org/10.1016/0360-3016(94)90104-X
  21. Franzen L, Funegard U, Ericson T, et al. Parotid gland function during and following radiotherapy of malignancies in the head and neck: a consecutive study of salivary flow and patient discomfort. Eur J Cancer 1992;28:457-462 https://doi.org/10.1016/S0959-8049(05)80076-0
  22. Marks JE, Davis CC, Gottsman VL, et al. The effects of radiation on parotid salivary function. Int J Radiat Oncol Biol Phys 1981;7:1013-1019 https://doi.org/10.1016/0360-3016(81)90152-8
  23. Longma LP, Highman SM, Bucknall R, et al. Signs and symptoms in patients with salivary gland hypofunction. Postgrad Med J 1997;73:93-97 https://doi.org/10.1136/pgmj.73.856.93
  24. Kosuda S, Satoh M, Yamamoto F, et al. Assessment of salivary gland dysfunction following chemoradiotherapy using quantitative salivary gland scintigraphy. Int J Radiat Oncol Biol Phys 1999;45:379-384 https://doi.org/10.1016/S0360-3016(99)00166-2
  25. Bjordal K, Ahlner-Elmqvist M, Tollesson E, et al. Development of European Organization for Research and Treatment of Cancer (EORTC) questionnaire module to be used in quality of life assessments in head and neck cancer patients: EORTC Quality of Life Study Group. Acta Oncol 1994;33:897- 885
  26. Cella DF, Tulsky DS, Gray G, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-579 https://doi.org/10.1200/JCO.1993.11.3.570
  27. Eisbruch A, Kim HM, Ten Haken R, et al. Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1996;45:577-587